记者 Bhanvi Satija 和 Sneha S K 马德里10月26日电 - 根据研究人员周一在一次医学会议上公布的数据，由翰森制药和葛兰素史克（GSK）共同开发的一种针对难治性骨癌的实验性药物，帮助患者在病情未恶化的情况下生存了更长时间。
By Bhanvi Satija and Sneha S K MADRID, Oct 26 - An experimental drug for a hard-to-treat bone cancer, being developed by Hansoh Pharmaceutical and GSK, helped patients live longer without the disease worsening, according to data presented by researchers at a medical meeting on Monday.
根据一项在中国进行的晚期临床研究，接受靶向癌症疗法药物 Ris-rez 治疗的患者，其无进展生存期中位数为5.5个月，而接受化疗的患者仅为1.4个月。
Patients on ris-rez, a type of targeted cancer therapy, lived a median of 5.5 months without their disease worsening, compared with 1.4 months for those on chemotherapy, according to a late-stage study conducted in China.
此类药物常被形容为“制导导弹”，因为它们能将杀伤细胞的药物直接输送至肿瘤，同时在很大程度上避开健康组织。
Such drugs are often described as "guided missiles" as they deliver cell-killing drugs directly to tumors while largely sparing healthy tissue.
Ris-rez 是葛兰素史克重建肿瘤学领域竞争力战略的核心，这距离该公司退出该领域已过去十年。葛兰素史克已从翰森制药获得该药物许可，并正在加速推进其在多种癌症中的开发。
Ris-rez is at the center of GSK's strategy to rebuild a competitive presence in oncology, a decade after exiting the space. The company has licensed the drug from Hansoh and is accelerating its development across several cancers.
该药物在122名年龄12岁及以上、既往接受过两线以上治疗后病情进展的复发难治性骨肉瘤患者中进行了测试。
The drug was tested in 122 patients, aged 12 and older, with relapsed refractory osteosarcoma who have progressed after more than two lines of prior treatment.
巴黎古斯塔夫·鲁西癌症中心的儿科肿瘤学家 Nathalie Gaspar 表示：“这是一项非常有趣的研究，可能会改变我们对骨肉瘤治疗的设想。”
It "is a very interesting study that might change the way that we will envision the treatment in osteosarcoma," said Nathalie Gaspar, paediatric oncologist at Paris-based Gustave Roussy.
担任该试验主要研究者的北京大学人民医院谢璐表示，该药物还使患者疾病进展或死亡的风险降低了67%。
The drug also showed a 67% reduction in the risk of disease progression or death in patients, said Lu Xie of Peking University People's Hospital, who was the lead researcher of the trial.
葛兰素史克肿瘤产品开发负责人 Eric Richards 在马德里举行的欧洲肿瘤内科学会（ESMO）年会间隙接受路透社采访时表示：“疗效幅度巨大。这让我们非常有信心，我们所期待的——即该药物在不同肿瘤中显示活性——很有可能会成真。”患者每三周接受一次12毫克剂量的该药物或化疗。
"The magnitude of effect is substantial," Eric Richards, who heads oncology product development at GSK, told Reuters on the sidelines of the European Society for Medical Oncology Congress in Madrid. "It gives us a lot of confidence that what we're hoping for — activity across these different tumors — is likely to come to fruition." Patients received a 12-milligram dose of the drug or chemotherapy once every three weeks.
在新任首席执行官卢克·米尔斯（Luke Miels）的带领下，葛兰素史克（GSK）正寻求将重点从血液和妇科治疗拓展至肺癌和前列腺癌等领域。该公司还在开发另一种名为 mo-rez 的实验性疗法，该疗法同样源自这家中国药企的授权，葛兰素史克认为其具有成为重磅药物的潜力。
GSK is seeking to broaden its focus beyond blood and gynaecological treatments into areas such as lung and prostate cancer under new CEO Luke Miels. It is also developing mo-rez, another experimental therapy licensed from the Chinese drugmaker that it believes has blockbuster potential.
在今年的大会上，葛兰素史克共有 21 份数据摘要，涵盖其合作开发的肺癌及其他癌症药物，而去年仅有 11 份。
At this year's Congress, GSK had 21 data abstracts, including for its partnered lung and other cancer drugs, compared to 11 last year.